Caron Jacobson

World-class lymphoma experts Anas Younes and Caron Jacobson discuss key updates on CAR T-cell therapy and precision medicine in non-Hodgkin lymphoma. They explore challenges and benefits, including drug screening, biomarker-driven trials, accessing CAR T-cell therapy, novel drugs like Brute NIB and anti-CD-79 conjugated antibody, studying bridging therapy, understanding T cell composition, and the impact of CAR T-cell therapy on patient enrollment and disease control.